AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25959570 — intervention group
Group type: EXPERIMENTAL
Intervention: Open posterolateral approach
Number of subjects: 23
Study 25959570 — intervention group
Group type: COMPARATOR
Intervention: Closed anterior-posterior screw fixation
Number of subjects: 23
Study 23449426 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day for 9 months
Number of subjects: 66
Study 23449426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20941634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-active glass air abrasion
Number of subjects: 38
Study 20941634 — intervention group
Group type: COMPARATOR
Intervention: Alumina air abrasion
Number of subjects: 38
Study 18840205 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 248
Study 16818810 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker therapy (control group)
Number of subjects: 94
Study 16818810 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus beta-blocker
Number of subjects: 94
Study 16818810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 94
Study 12507797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory drug testing (DT)
Number of subjects: 276
Study 12507797 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - No mandatory drug testing
Number of subjects: 276
Study 10688394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% BID
Number of subjects: 94
Study 10688394 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 94
Study 9449474 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant IFN-beta1a (3 MIU or 9 MIU subcutaneously 3x a week)
Number of subjects: 68
Study 7993150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 12
Study 3282670 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg/day)
Number of subjects: 70
Study 3282670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30515995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - one telephone session
Number of subjects: 112
Study 30515995 — intervention group
Group type: COMPARATOR
Intervention: Reminder calls (Control)
Number of subjects: 112
Study 30515995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - two sessions (one telephone and one in person)
Number of subjects: 112
Study 28490725 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 68
Study 28490725 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 68
Study 26150167 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-fit, ultralightweight manual wheelchairs with propulsion/skills training and support calls
Number of subjects: 14
Study 26150167 — intervention group
Group type: COMPARATOR
Intervention: No training, using own wheelchairs
Number of subjects: 14
Study 21649520 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, water‐based herbal decoctions (Verum group)
Number of subjects: 102
Study 21649520 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific presumably ineffective, water‐based herbal decoctions (Control group)
Number of subjects: 102
Study 21649520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Verum and Control)
Number of subjects: 102
Study 17934824 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 83
Study 17934824 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde pancreatography (ERP)
Number of subjects: 83
Study 16507849 — intervention group
Group type: EXPERIMENTAL
Intervention: as-needed formoterol 4.5 microg Turbuhaler
Number of subjects: 211
Study 16507849 — intervention group
Group type: COMPARATOR
Intervention: as-needed salbutamol 100 microg Turbuhaler
Number of subjects: 211
Study 12946491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone (80 mg)
Number of subjects: 60
Study 12946491 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine 5% (15 puffs)
Number of subjects: 60
Study 15017487 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily mesalamine (QD)
Number of subjects: 22
Study 15017487 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing mesalamine (CD)
Number of subjects: 22
Study 9925862 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (150 IU/kg/d, 3 times a week, subcutaneously) for 2 months
Number of subjects: 34
Study 9925862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rHuEPO)
Number of subjects: 34
Study 9925862 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO in non-CDDP chemotherapy regimens
Number of subjects: 34
Study 9925862 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO in CDDP-containing regimens
Number of subjects: 34
Study 8800821 — intervention group
Group type: COMPARATOR
Intervention: Naloxone at 10% or less of the 24 h dose of morphine (placebo controlled)
Number of subjects: 17
Study 8800821 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone at 20% of the 24 h dose of morphine
Number of subjects: 17
Study 8800821 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone at maximum doses of 20%, 40%, and 80% of the 24 h dose of morphine
Number of subjects: 17
Study 1386766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% foaming gel
Number of subjects: 62
Study 1386766 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05% lotion
Number of subjects: 62
Study 6731019 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrography performed after reduction of the dislocation
Number of subjects: 14
Study 6731019 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with exploration and suture of both the ulnar and the radial collateral ligaments (randomized half of the patients)
Number of subjects: 14
Study 6731019 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage of the contrast medium
Number of subjects: 14
Study 3728637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pierce saccade test (group I initial testing)
Number of subjects: 63
Study 3728637 — intervention group
Group type: EXPERIMENTAL
Intervention: King-Devick saccade test (group I initial testing)
Number of subjects: 63
Study 3728637 — intervention group
Group type: COMPARATOR
Intervention: Pierce saccade test (group I retest)
Number of subjects: 63
Study 3728637 — intervention group
Group type: COMPARATOR
Intervention: King-Devick saccade test (group I retest)
Number of subjects: 63
Study 3728637 — intervention group
Group type: COMPARATOR
Intervention: Pierce saccade test (group II initial testing)
Number of subjects: 63
Study 3728637 — intervention group
Group type: COMPARATOR
Intervention: King-Devick saccade test (group II initial testing)
Number of subjects: 63
Study 31326629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver blood reinfused intraoperatively
Number of subjects: 89
Study 31326629 — intervention group
Group type: COMPARATOR
Intervention: Allogenic blood
Number of subjects: 89
Study 31326629 — intervention group
Group type: COMPARATOR
Intervention: Visible blood loss (EBL and blood loss from drains)
Number of subjects: 89
Study 28954455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibelium in combination with dibazole
Number of subjects: 136
Study 28954455 — intervention group
Group type: COMPARATOR
Intervention: Sibelium only (Control)
Number of subjects: 136
Study 25726404 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized slide show and short videotape presentation
Number of subjects: 70
Study 25726404 — intervention group
Group type: COMPARATOR
Intervention: Modified informed consent document without videotape
Number of subjects: 70
Study 24494330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonic voice samples
Number of subjects: 40
Study 24494330 — intervention group
Group type: COMPARATOR
Intervention: Normal voice samples
Number of subjects: 40
Study 21461638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 U [0.2 ml])
Number of subjects: 32
Study 21461638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 ml)
Number of subjects: 32
Study 19232896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus eptifibatide
Number of subjects: 200
Study 19232896 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 200
Study 16822101 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent bibliotherapy (written materials for parents)
Number of subjects: 267
Study 16822101 — intervention group
Group type: COMPARATOR
Intervention: Standard group treatment
Number of subjects: 267
Study 16822101 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 267
Study 15545047 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat products enriched with plant sterols (1.2 g/day), potassium, calcium and magnesium (MP1)
Number of subjects: 21
Study 15545047 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat products with plant sterols (2.1 g/day), potassium, calcium and magnesium (MP2)
Number of subjects: 21
Study 15545047 — intervention group
Group type: COMPARATOR
Intervention: Control meat products (no added plant sterols and minerals)
Number of subjects: 21
Study 15545047 — intervention group
Group type: COMPARATOR
Intervention: Meat products with no added plant sterols and minerals (control)
Number of subjects: 21
Study 15545047 — intervention group
Group type: EXPERIMENTAL
Intervention: All test periods
Number of subjects: 21
Study 11545671 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) - educational videotapes and pamphlets; pharmacotherapy with paroxetine; 2 psychiatrist visits and 2 telephone calls in the first 8 weeks; up to 5 telephone calls between 3 and 12 months' follow-up
Number of subjects: 115
Study 11545671 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - treated by primary care physician
Number of subjects: 115
Study 11545671 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 115
Study 11545671 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 115
Study 9243340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally-oriented (HSB) individual counseling style
Number of subjects: 16
Study 9243340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-structure, facilitative (LSF) individual counseling style
Number of subjects: 16
Study 9243340 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping measures (conceptual and developmental levels of functioning, field independence, social independence)
Number of subjects: 16
Study 8494706 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (100 mg tds orally)
Number of subjects: 60
Study 8494706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3480298 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with teflon membrane placement
Number of subjects: 37
Study 3480298 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without teflon membrane
Number of subjects: 37
Study 29780236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered once
Number of subjects: 60
Study 29780236 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered twice
Number of subjects: 60
Study 29780236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FDC and co-administration)
Number of subjects: 60
Study 25967606 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (1.5-g daily)
Number of subjects: 80
Study 25967606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25529502 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagram‐Based Restudy (DBR)
Number of subjects: 128
Study 25529502 — intervention group
Group type: COMPARATOR
Intervention: Text‐Based Restudy (TBR)
Number of subjects: 128
Study 22562983 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+TCZ (tocilizumab 8 mg/kg every 4 weeks)
Number of subjects: 556
Study 22562983 — intervention group
Group type: COMPARATOR
Intervention: TCZ+PBO (tocilizumab and placebo)
Number of subjects: 556
Study 22562983 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+TCZ
Number of subjects: 556
Study 22562983 — intervention group
Group type: COMPARATOR
Intervention: TCZ+PBO
Number of subjects: 556
Study 21968126 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 17802
Study 21968126 — intervention group
Group type: EXPERIMENTAL
Intervention: prediction based treatment
Number of subjects: 17802
Study 21968126 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study 18721079 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 19
Study 18721079 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 19
Study 16792053 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser (KEY 3, KaVo)
Number of subjects: 72
Study 16792053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (Piezon Master 400, EMS)
Number of subjects: 72
Study 16792053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic scaler (Sonicflex 2003 L, KaVo)
Number of subjects: 72
Study 16792053 — intervention group
Group type: COMPARATOR
Intervention: Control (Gracey Mini-five curettes, Hu Friedy)
Number of subjects: 72
Study 12923797 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural audiotape
Number of subjects: 0
Study 12923797 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping audiotape
Number of subjects: 0
Study 12923797 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional audiotape
Number of subjects: 0
Study 10863968 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation of the spermatic vein
Number of subjects: 75
Study 10863968 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated varicocele patients)
Number of subjects: 75
Study 9160025 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece PMMA IOL
Number of subjects: 225
Study 9160025 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece silicone IOL
Number of subjects: 225
Study 9160025 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece acrylic soft IOL
Number of subjects: 225
Study 9160025 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study 8370428 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐38,485 (600 mg daily)
Number of subjects: 10
Study 8370428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8370428 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐38,485
Number of subjects: 10
Study 3776260 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 31532518 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one PRISM-P intervention
Number of subjects: 94
Study 31532518 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PRISM-P intervention
Number of subjects: 94
Study 31532518 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study 28027333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly updated personalized antibiotic prescription feedback over 2 years (n=1450)
Number of subjects: 2900
Study 28027333 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=1450)
Number of subjects: 2900
Study 25893955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhibition of nitric oxide (NO) and prostaglandin (PG) synthesis (l-NMMA + ketorolac)
Number of subjects: 17
Study 25893955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined KIR channel and Na(+) /K(+) -ATPase inhibition (l-NMMA + ketorolac + BaCl2 + ouabain)
Number of subjects: 17
Study 25893955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined KIR channel and Na(+) /K(+) -ATPase inhibition
Number of subjects: 17
Study 25893955 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 17
Study 22864846 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleStroke network hospitals (intervention)
Number of subjects: 1277
Study 22864846 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1277
Study 21563505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine for 12 weeks
Number of subjects: 80
Study 21563505 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen Sodium Tablet and Leifumite Tablet for 12 weeks
Number of subjects: 80
Study 19571082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge with ceramic granules; total dose of rhBMP-2, 12 mg.
Number of subjects: 46
Study 19571082 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft (control group).
Number of subjects: 46
Study 16776758 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional warm vertical compaction technique using Touch'n Heat and Obtura II.
Number of subjects: 60
Study 16776758 — intervention group
Group type: COMPARATOR
Intervention: Modified warm vertical compaction technique with apical back-filling.
Number of subjects: 60
Study 15478678 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-guided BOTOX injection
Number of subjects: 15
Study 15478678 — intervention group
Group type: COMPARATOR
Intervention: Non EMG-guided BOTOX injection
Number of subjects: 15
Study 11012480 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Amoxycillin 1 g b.d. (RLA group)
Number of subjects: 100
Study 11012480 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Tinidazole 500 mg b.d. (RLT group)
Number of subjects: 100
Study 11012480 — intervention group
Group type: EXPERIMENTAL
Intervention: RLA group
Number of subjects: 100
Study 11012480 — intervention group
Group type: EXPERIMENTAL
Intervention: RLT group
Number of subjects: 100
Study 9330929 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ with MTX as needed for disease flare (n = 40)
Number of subjects: 121
Study 9330929 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ 400 mg/day (n = 41)
Number of subjects: 121
Study 9330929 — intervention group
Group type: COMPARATOR
Intervention: Placebo with MTX as needed for disease flare (n = 40)
Number of subjects: 121
Study 8452164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg once daily
Number of subjects: 301
Study 8452164 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin, 400 mg twice daily
Number of subjects: 301
Study 2429466 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 X 200 mg)
Number of subjects: 20
Study 2429466 — intervention group
Group type: COMPARATOR
Intervention: Prajmalium-bitartrate (4 X 20 mg)
Number of subjects: 20
Study 30053196 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week home-based aerobic exercise program (EX)
Number of subjects: 41
Study 30053196 — intervention group
Group type: COMPARATOR
Intervention: 6-week self-administered cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 41
Study 30053196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (EX and CBT-I)
Number of subjects: 41
Study 27184020 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week ultrasound examination
Number of subjects: 30000
Study 27184020 — intervention group
Group type: COMPARATOR
Intervention: 18-week ultrasound examination
Number of subjects: 30000
Study 25041791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg/week intravenously), Erlotinib (100 mg/day orally), Gemcitabine (1000 mg/m2 intravenously on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 116
Study 25041791 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus Gemcitabine (control arm)
Number of subjects: 116
Study 25041791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Number of subjects: 116
Study 25041791 — intervention group
Group type: COMPARATOR
Intervention: Control (Erlotinib plus Gemcitabine)
Number of subjects: 116
Study 25041791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab and Control
Number of subjects: 116
Study 22327716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular thrombolysis with rt-PA (Actilyse(®)) 5 mg every 12 h and lateral rotational therapy (RotoRest(®))
Number of subjects: 40
Study 22327716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 20580767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants (Ketac Molar Easymix) without energy supplied
Number of subjects: 89
Study 20580767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants (with energy supplied)
Number of subjects: 89
Study 20580767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 89
Study 20580767 — intervention group
Group type: COMPARATOR
Intervention: Resin composite sealants
Number of subjects: 89
Study 18078880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early unrestricted weight bearing combined with intensive physiotherapy
Number of subjects: 42
Study 18078880 — intervention group
Group type: COMPARATOR
Intervention: Partial weight bearing combined with self-training
Number of subjects: 42
Study 16245505 — intervention group
Group type: EXPERIMENTAL
Intervention: ThromboCheck device monitoring
Number of subjects: 291
Study 16245505 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 291
Study 12125943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ointment (calcipotriol/betamethasone dipropionate)
Number of subjects: 1106
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment (Diprosone)
Number of subjects: 1106
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment (Daivonex)
Number of subjects: 1106
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Combination ointment vs Betamethasone
Number of subjects: 1106
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Combination ointment vs Calcipotriol
Number of subjects: 1106
Study 12125943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ointment
Number of subjects: 1106